EAN 2021 | Enhancing convenience and flexibility with SC natalizumab for MS

Bart Van Wijmeersch, MD, PhD, Rehabilitation and MS Center Overpelt & University of Hasselt, Hasselt, Belgium, discusses subcutaneous (SC) natalizumab for patients with relapsing forms of multiple sclerosis (MS). Natalizumab, a humanized monoclonal antibody directed against the α4-integrin cell adhesion molecule, is a highly effective treatment that has been used for many years in an intravenous (IV) formulation. Recently, SC natalizumab was approved by the European Medicines Agency. In clinical trials, the SC formulation has shown comparability to the IV administration in efficacy and safety. Additionally, the new formulation is convenient to patients as it reduces the time spent receiving treatment. This interview took place during the European Academy of Neurology 2021 congress.